Category: Data Analysis and Informatics
Scientists and engineers from two U.S. national laboratories, industry, and academia today launched an unprecedented effort to transform the way cancer drugs are discovered by creating an open and sharable platform that integrates high-performance computing, shared biological data from public and industry sources, and emerging biotechnologies to dramatically accelerate the discovery of effective cancer therapies. The goal of the consortium – Accelerating Therapeutics for Opportunities in Medicine (ATOM) – is to create a new paradigm of drug discovery that would reduce the time from an identified drug target to clinical candidate from the current approximately six years to just one year. This goal is tightly aligned with those of the 21st Century Cures Act, which aims in part to enable a greater number of therapies to reach more patients more quickly. ATOM aims to transform cancer drug discovery from a time-consuming, sequential, and high-risk process into an approach that is rapid, integrated, and with better patient outcomes -- using supercomputers to pretest many molecules simultaneously for safety and efficacy. Currently, the consortium comprises the Department of Energy’s Lawrence Livermore National Laboratory (LLNL), GSK, the National Cancer Institute’s Frederick National Laboratory for Cancer Research (FNLCR), and the University of California, San Francisco (UCSF) with different technical and research contributions, while ATOM welcomes and continues to seek additional public and private partners who share the vision. ATOM will develop, test, and validate a multidisciplinary approach to drug discovery in which modern science, technology and engineering, supercomputing simulations, data science, and artificial intelligence are highly integrated into a single drug-discovery platform that can ultimately be shared with the drug development community at large. In this poster, this unique and innovative initiative and strategy to accelerate the discovery of effective cancer therapies will be presented and promoted.
Claire Jeong– Complex In Vitro Models Expert/Investigator, ATOM consortium, San Francisco, CA